Tremelimumab and durvalumab for MSI-H gastric cancer
Yakup Ergün, Medical Oncologist at Bower Hospital, shared a paper by Raimondi et al. on X:
“Tremelimumab and durvalumab as neoadjuvant or non-operative management of pts with MSI-H resectable gastric/GEJ adenocarcinoma: the INFINITY study by GONO.
Cohort 1: pCR 60% (T4:pCR:17%)
Cohort 2: cCR 76% and NOM (1 pt local regrowth)
MSI-H=ICI.”
Authors: A. Raimondi, S. Lonardi, S. Murgioni, G.G. Cardellino, S. Tamberi, A. Strippoli, F. Palermo, G. De Manzoni, M. Bencivenga, A. Bittoni, C. Chiodoni, D. Lorenzini, K. Todoerti, P. Manca, S. Sangaletti, M. Prisciandaro, G. Randon, F. Nichetti, F. Bergamo, S. Brich, A. Belfiore, A. Bertolotti, D. Stetco, A. Guidi, T. Torelli, A. Vingiani, R.P. Joshi, M. Khoshdeli, N. Beaubier, M.C. Stumpe, F. Nappo, A.G. Leone, C.C. Pircher, G. Leoncini, G. Sabella, L. Airo’ Farulla, A. Alessi, F. Morano, A. Martinetti, M. Niger, M. Fassan, M. Di Maio, K. Kaneva, M. Milione, H. Nimeiri, C. Sposito, L. Agnelli, V. Mazzaferro, M. Di Bartolomeo, F. Pietrantonio
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023